IP Library Granted Patent US 8,692,002
Granted Patent B2
US 8,692,002 · App. 11/719,737 · Granted Apr 8, 2014

Synthetic process for aminocyclohexyl ether compounds

Inventors: Bertrand M. C. Plouvier (Vancouver, CA); Doug Ta Hung Chou (Vancouver, CA); Grace Jung (New Westminster, CA); Lewis Siu Leung Choi (Burnaby, CA); Tao Sheng (Westwood, MA); Anthony G. M. Barrett (Chiswick, GB); Marco S. Passafaro (Thayngen, CH); Martin Kurz (Schaffhausen, CH); Daniel Moeckli (Schlatt, CH); Pirmin Ulmann (Dachsen, CH); Alfred Hedinger (Thayngen, CH)
Assignee: Cardiome Pharma Corp.
C07D207/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,692,002
App. No.
11/719,737
Granted
Apr 8, 2014
Kind
B2
Abstract

Methods for the preparation of stereoisomerically substantially aminocyclohexyl ether compounds such as trans-(1R,2R)-aminocyclohexyl ether compounds and/or trans-(1S,2S)-aminocyclohexyl ether compounds as well as various intermediates and substrates are disclosed.

Claims (18)

1. A method of stereoselectively making a compound of formula (18):

or a pharmaceutically acceptable salt thereof, which method comprises:

(a) treating a compound of formula (12):

to resolution conditions to yield a compound of formula (14):

where Bn is benzyl;

(b) reacting the compound of formula (14) with a compound of formula (16):

where Me is methyl, under suitable conditions comprising the presence of a Lewis acid or a Bronsted acid such that upon reaction of the compound of formula (14) with the compound of formula (16), the stereochemical configuration of the carbon to which the hydroxyl group is attached in the compound of formula (14) is retained in the resulting compound of formula (17):

where Bn is benzyl and Me is methyl;

(c) removing the benzyl from the compound of formula (17) under suitable conditions to form a compound of formula (18), as described above; and

(d) optionally converting the compound of formula (18) under suitable conditions to a pharmaceutically acceptable salt.

2. The method of claim 1 further comprising a method of making the compound of formula (12) wherein the method comprises reacting a compound of formula (11):

where Bn is benzyl, or a pharmaceutically acceptable salt thereof; with a compound of formula (1):

under suitable conditions to form a compound of formula (12).

3. The method of claim 1 further comprising a method of making the compound of formula (16) wherein the method comprises treating a compound of formula (15):

where Me is methyl, with trichloroacetonitrile under suitable conditions to form the compound of formula (16).

4. The method of claim 1 wherein the resolution conditions are chiral resolution conditions.

5. The method of claim 4 wherein the chiral resolution conditions comprise first treating the compound of formula (12) with di-O,O-p-toluoyl-L-tartaric acid under suitable conditions to form a mixture of diastereomeric salts and then isolating the compound of formula (14) from the mixture.

6. The method of claim 1 wherein the resolution conditions are kinetic resolution conditions.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2018
From: CARDIOME PHARMA CORP.
To: CORREVIO CANADA CORP.
Reel/Frame 046831/0078 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2018
From: CORREVIO CANADA CORP.
To: CORREVIO INTERNATIONAL SÀRL
Reel/Frame 046831/0227 →
RELEASE OF SECURITY INTEREST Recorded Jun 20, 2016
From: MIDCAP FINANCIAL TRUST
To: CARDIOME PHARMA CORP.; CARDIOME, INC.; ARTESIAN THERAPEUTICS, INC.; MURK ACQUISITION SUB, INC.; CORREVIO LLC; CARDIOME INTERNATIONAL AG; CORREVIO INTERNATIONAL SARL; CORREVIO (UK) LTD.; CARDIOME UK LIMITED; CORREVIO (AUSTRALIA) PTY LTD.
Reel/Frame 038961/0202 →
SECURITY INTEREST Recorded Jul 24, 2014
From: CARDIOME PHARMA CORP.; CARDIOME, INC.; ARTESIAN THERAPEUTICS, INC.; MURK ACQUISITION SUB, INC.; CORREVIO LLC; CARDIOME INTERNATIONAL AG; CORREVIO INTERNATIONAL SARL; CORREVIO (UK) LTD.; CARDIOME UK LIMITED; CORREVIO (AUSTRALIA) PTY LTD.
To: MIDCAP FUNDING V, LLC
Reel/Frame 033407/0314 →
Continuity (3)
Provisional Application 60629526 · Nov 18, 2004
Provisional Application 60705716 · Aug 3, 2005
Related Publication 20100152464A1 · Jun 17, 2010